TY  - JOUR
T1  - TOward a safer cure for low-risk hodgkin lymphoma in children
AU  - Whelan KF, Goldman FD
Y1  - 2012/06/27
N1  - 10.1001/jama.2012.6975
JO  - JAMA
SP  - 2639
EP  - 2641
VL  - 307
IS  - 24
N2  - 
Currently children and adolescents diagnosed with Hodgkin lymphoma have 5-year overall survival rates greater than 90%.1- 2 Therapeutic approaches to Hodgkin lymphoma have evolved, from high-dose extended-field radiation to dose-intensive combination chemotherapy regimens (which relied heavily on alkylating agent exposure), to the current standard of care for all stages of disease in children using multiagent chemotherapy combined with low-dose involved field radiation therapy (IFRT).1 This evolution has been driven by recognition that these curative regimens have been accompanied by significant late treatment–related complications, including secondary malignancies, cardiovascular disease, pulmonary fibrosis, thyroid dysfunction, and gonadal toxicity.2- 4 These late effects significantly influence the quality of life for survivors of Hodgkin lymphoma.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.6975
UR  - http://dx.doi.org/10.1001/jama.2012.6975
ER  -